Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia

G B Martinelli1, D Olivari1, A D Re Cecconi1

  • 1Department of Oncology, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.

Oncogene
|May 24, 2016
PubMed

Insights

Activating the CXCR4 pathway in muscle combats cancer cachexia by preventing muscle wasting. This involves regulating stromal cell-derived factor 1 (SDF1) and its receptor, offering a potential therapeutic target for this severe condition.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Cancer cachexia is a severe, life-threatening syndrome causing significant muscle and body weight loss in advanced cancer patients.
  • Currently, no effective treatments are available for cancer cachexia, highlighting an urgent need for therapeutic strategies.

Purpose of the Study:

  • To identify specific molecular pathways altered in cancer cachexia.
  • To investigate the role of the CXCR4 pathway in muscle wasting associated with cancer.
  • To explore potential therapeutic targets for combating cancer cachexia.

Main Methods:

  • Analysis of microarray data from cachectic rodent muscles and human tissues.
  • Ingenuity Pathways Analysis to identify dysregulated genes and pathways.
  • Gene expression correlation studies with ubiquitin ligases in cancer patient muscles.
  • In vivo and in vitro experiments involving gene overexpression and pathway inhibition in muscle models.

Main Results:

  • Downregulation of stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1) in cachectic muscles, linked to the CXCR4 pathway.
  • Inverse correlation between SDF1/CXCR4 expression and muscle-wasting ubiquitin ligases (atrogin-1, MuRF1) in cancer patients.
  • Overexpressing SDF1 or CXCR4 increased muscle fiber area by 20% and protected against wasting.
  • SDF1 treatment reduced protein degradation in atrophying myotubes, while CXCR4 inhibition affected normal myotubes, confirming pathway involvement.

Conclusions:

  • The CXCR4 pathway, specifically involving SDF1, plays a critical role in suppressing cancer-induced muscle wasting.
  • Activating the CXCR4 pathway in muscle represents a promising therapeutic strategy to counteract cancer cachexia.
  • Findings suggest targeting the SDF1-CXCR4 axis could offer a novel treatment for cancer cachexia.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
124.5K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K